Angiotensinogen (AGT) Antibody Pair

Background

Angiotensinogen (AGT) is a protein primarily produced and secreted by the liver, although it is also synthesized by other tissues, including the kidney and adipose tissue. It serves as the precursor molecule for the renin-angiotensin system (RAS), a key regulatory pathway involved in blood pressure regulation, fluid balance, and electrolyte homeostasis. AGT is converted into angiotensin I by the enzyme renin, which is released by the kidneys in response to various stimuli, such as decreased blood pressure or sodium levels. Angiotensin I is further converted into angiotensin II by angiotensin-converting enzyme (ACE), leading to vasoconstriction, aldosterone release, and sodium reabsorption, ultimately raising blood pressure. Dysregulation of the RAS, including alterations in AGT levels, has been implicated in hypertension, cardiovascular disease, and kidney disorders. Therapeutic interventions targeting the RAS, such as ACE inhibitors and angiotensin receptor blockers, are commonly used to manage hypertension and related conditions. Understanding the role of AGT in the RAS provides insights into cardiovascular health and potential avenues for therapeutic intervention. Ongoing research continues to elucidate the intricate mechanisms underlying AGT regulation and its implications for human health and disease